Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas

Background. Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results. Patients and Methods. Analysis of consecutive patients with neuroendocrine carc...

Descripción completa

Detalles Bibliográficos
Autores principales: Olsen, Ingrid H., Sørensen, Jens B., Federspiel, Birgitte, Kjaer, Andreas, Hansen, Carsten P., Knigge, Ulrich, Langer, Seppo W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Scientific World Journal 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432352/
https://www.ncbi.nlm.nih.gov/pubmed/22973169
http://dx.doi.org/10.1100/2012/170496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432352/
https://www.ncbi.nlm.nih.gov/pubmed/22973169
http://dx.doi.org/10.1100/2012/170496

Ejemplares similares